GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytori Cell Research Institute Inc (TSE:3750) » Definitions » Debt-to-EBITDA

Cytori Cell Research Institute (TSE:3750) Debt-to-EBITDA : -26.18 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cytori Cell Research Institute Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cytori Cell Research Institute's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円919 Mil. Cytori Cell Research Institute's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円6,843 Mil. Cytori Cell Research Institute's annualized EBITDA for the quarter that ended in Dec. 2023 was 円-296 Mil. Cytori Cell Research Institute's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -26.18.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cytori Cell Research Institute's Debt-to-EBITDA or its related term are showing as below:

TSE:3750' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -32.59   Med: 3.42   Max: 26.57
Current: -9.31

During the past 13 years, the highest Debt-to-EBITDA Ratio of Cytori Cell Research Institute was 26.57. The lowest was -32.59. And the median was 3.42.

TSE:3750's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.34 vs TSE:3750: -9.31

Cytori Cell Research Institute Debt-to-EBITDA Historical Data

The historical data trend for Cytori Cell Research Institute's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytori Cell Research Institute Debt-to-EBITDA Chart

Cytori Cell Research Institute Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.82 15.93 -32.59 26.57 -12.06

Cytori Cell Research Institute Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.65 -5.07 -16.54 -9.88 -26.18

Competitive Comparison of Cytori Cell Research Institute's Debt-to-EBITDA

For the Biotechnology subindustry, Cytori Cell Research Institute's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytori Cell Research Institute's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytori Cell Research Institute's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cytori Cell Research Institute's Debt-to-EBITDA falls into.



Cytori Cell Research Institute Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cytori Cell Research Institute's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(901.237 + 7605.855) / -705.344
=-12.06

Cytori Cell Research Institute's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(918.765 + 6843.099) / -296.444
=-26.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Cytori Cell Research Institute  (TSE:3750) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cytori Cell Research Institute Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cytori Cell Research Institute's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytori Cell Research Institute (TSE:3750) Business Description

Traded in Other Exchanges
N/A
Address
1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
Cytori Cell Research Institute Inc developing a new clinical approach to cell therapy to provide better medical care to patients by providing medical care that responds to unmet medical needs based on innovative regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.

Cytori Cell Research Institute (TSE:3750) Headlines

No Headlines